Table 1 Baseline characteristics of study participants
From: Evaluation of iron stores in hemodialysis patients on maintenance ferric Carboxymaltose dosing
All | 100 mg FCM | 200 mg FCM | p-value* | |
|---|---|---|---|---|
n = 19 | n = 12 | |||
Age, years (range) | 63.9 (34–84) | 66.2 (46–84) | 60.25 (34–80) | 0.2 |
Male gender, n (%) | 17 (54.8) | 10 (52.6) | 7 (58.3) | 0.8 |
BMI, kg/m2 | 27.5 (7.4) | 27.3 (8.6) | 27.9 (5.4) | 0.8 |
Dialysis Vintage, month | 41.7 (34.3) | 50 (38.1) | 28.4 (22.9) | 0.5 |
Erythropoiesis stimulating agents n (%) | 28 (90.3) | 16 (84.2) | 12 (100) | |
Dose darbepoetin alfa, μg/week | 25.9 (14.7) | 28.6 (13.8) | 22.3 (15) | 0.27 |
Baseline laboratory parameters | ||||
Ferritin, μg/l, median (IQR) | 425 (291–548) | 450 (390–573) | 313 (193–538) | 0.3 |
TSAT, %, median (IQR) | 27 (21.8–30.8) | 26.1 (20.7–28.4) | 29.0 (23.1–31.8) | 0.3 |
Hemoglobin, g/l | 109.5 (8.9) | 107.5 (8.2) | 112.8 (9.3) | 0.1 |
CRP, mg/l, median (IQR) | 2 (2–5) | 2 (2–7) | 3 (1.25–4) | 0.7 |
PTH, pmol/l1, median (IQR) | 30.4 (18.6–44.5) | 32.2 (11.5–44.5) | 27.5 (20.3–55.6) | 0.5 |
Vascular access, n (%) | ||||
AV-Fistula | 24 (77.4) | 13 (68.4) | 11 (91.7) | |
AV-Graft | 3 (9.7) | 3 (15.8) | 0 (0) | |
Catheter | 4 (12.9) | 3 (15.8) | 1 (8.3) | |
Primary cause of ESRD | ||||
Diabetes | 8 (25.8) | 3 (15.8) | 4 (33.3) | |
Hypertension | 3 (9.7) | 2 (10.5) | 1 (8.3) | |
PKD | 1 (3.2) | 1 (5.3) | 0 | |
GN | 5 (16.1) | 5 (26.3) | 0 | |
Interstitial KD | 3 (9.7) | 3 (15.8) | 0 | |
CAKUT | 4 (12.9) | 1 (5.3) | 2 (16.7) | |
Other/unknown | 7 (22.6) | 4 (21.1) | 5 (41.7) | |
Comorbidity, n (%) | ||||
History of Cancer | 11 (35.5) | 8 (42.1) | 3 (25) | |
Chronic heart failure | 8 (25.8) | 6 (31.6) | 2 (16.7) | |
Peripheral artery disease | 9 (29.0) | 7 (36.8) | 2 (16.7) | |
Diabetes, n (%) | 13 (41.9) | 9 (47.4) | 4 (33.3) |